Article Text

Download PDFPDF

443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response
  1. Bernard Fox1,
  2. Tarsem Moudgil1,
  3. Traci Hilton2,
  4. Noriko Iwamoto3,
  5. Christopher Paustian2,
  6. Adi Mehta4,
  7. Fridtjof Lund-Johansen4,
  8. Rachel Sanborn1,
  9. Bryan Bell1,
  10. Madeleine Laws2,
  11. Glenna McDonnell2,
  12. Yoshinobu Koguchi1,
  13. Carlo Bifulco1,
  14. Brian Piening1,
  15. Carmen Ballesteros Merino1,
  16. Shawn Jensen1,
  17. Takashi Shimada3,
  18. Hong-Ming Hu1,
  19. Walter Urba1,
  20. Rom Leidner1,
  21. Marcus Couey1 and
  22. Marcus Couey1
  1. 1Earle A. Chiles Research Institute, Prov, Portland, OR, USA
  2. 2UbiVac, Portland, OR, USA
  3. 3Shimadzu Scientific Instruments, Bothell, WA, USA
  4. 4Oslo University Hospital Rikshospitalet, Oslo, Norway


Background Outcomes for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are dismal and responses to anti-PD-1 appear best in tumors with PD-1+ T cells in proximity to PD-L1+ cells, arguing that improved outcome is associated with a pre-existing anti-cancer immune response. Based on this, we hypothesize that vaccines which prime and/or expand T cells to a spectrum of antigens overexpressed by HNSCC combined with T cell agonists, like anti-GITR, that provide costimulatory signals will improve the anti-PD-1 response rates. We have developed a cancer vaccine, DPV-001, that contains more than 300 proteins for genes overexpressed by HNSCC, encapsulated in a CLEC9A-targeted microvesicle and containing TLR/NOD agonists and DAMPs. Recently, we reported that combining anti-GITR + vaccine + anti-PD-1 augmented therapeutic efficacy in a preclinical model and now plan a phase 1b trial of this combination in patients with advanced HNSCC.

Methods Sera from patients receiving DPV-001 as adjuvant therapy for definitively treated NSCLC, were analyzed for IgG responses to human proteins by MAP bead arrays and results compared to TCGA gene expression data sets for HNSCC. HNSCC cell lines were evaluated by RNASeq and peptides were eluted from HLA, analyzed by mass spectroscopy and correlated against MAP bead arrays and TCGA data sets. Tumor-reactive T cells from a vaccinated patient were enriched and expanded, and used in cytokine release assay (CRA) against autologous NSCLC and partially HLA matched allogeneic HNSCC cell lines.

Results Patients receiving DPV-001 (N=13) made 147 IgG responses to at least 70 proteins for genes overexpressed by HNSCC. Preliminary evaluation of the HNSCC peptidome against the results of MAP bead array identify antigens that are target of a humoral immune response. Additionally, tumor-reactive T cells from DPV-001 vaccinated patient recognize two partially HLA-matched HNSCC targets, but not a mis-matched target.

Conclusions Recent observations from our lab and others have correlated IgG Ab responses with T cell responses to epitopes of the same protein. Based on the data summarized above, we hypothesize that we have induced T cell responses against a broad spectrum of shared cancer antigens that are common among adenocarcinomas and squamous cell cancers. Our planned clinical trial will vaccinate and boost the induced responses by costimulation with anti-GITR and then sequence in delayed anti-PD-1 to relieve checkpoint inhibition. MAP bead arrays and the peptidome library generated above will be used to assess anti-cancer B and T cell responses.

Trial Registration NCT04470024

Ethics Approval The original clinical trial was approved by the Providence Portland Medical Center IRB, approval # 13-046. The proposed clinical trial has not yet been reviewed by the IRB.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.